Investing in Health Equity | Why New Jersey Should Cover FDA-Approved Medications Through Medicaid

March 2026

New Jersey is at a critical inflection point.
Like many states, obesity is on the rise in
New Jersey, increasing by roughly 6% over
the past decade. Without action, these
rates could skyrocket, furthering a health
equity crisis, and posing a threat to the
state’s Medicaid program, public health
infrastructure, and long-term economic
stability

Investing in Health Equity | Why New York Should Cover FDA-Approved Anti-Obesity Medications Through Medicaid

March 2026

New York faces an urgent challenge: without early, evidence-based intervention, today’s obesity crisis will become tomorrow’s diabetes, cardiovascular disease, or disability crisis all leading to ballooned Medicaid expenditures.

Protect Maryland’s Future | Why Maryland’s
Medical Assistance Program Should Cover
FDA-Approved Anti-Obesity Medications

February 2026

Expanding Maryland Medicaid to ensure
access to comprehensive,
evidence-based obesity treatments would
improve health outcomes, strengthen
health equity, and help reduce long-term
healthcare costs.

Investing in Health Equity | Why New Mexico Should Cover FDA-Approved Anti-Obesity Medications Through Medicaid

February 2026

New Mexico has an opportunity to take decisive action to support Medicaid coverage of FDA-approved AOMs.

Comprehensive Care Necessary to Successfully Treat Disease of Obesity

September 2024

Healthy eating is associated with lower rates of obesity. However, people experiencing poverty struggle to regularly afford critical healthy food items such as proteins, raw fruits, and vegetables.